The Future of GSD Ia: Emerging Treatments and Hope
At a Glance
Emerging treatments for Glycogen Storage Disease Type Ia (GSD Ia) are focusing on fixing the underlying genetic cause rather than just managing symptoms. Promising research includes AAV gene therapy to deliver healthy G6PC1 genes, CRISPR base editing, and new liver and kidney medications.
While the daily routine of managing Glycogen Storage Disease Type Ia (GSD Ia) is currently intensive, the landscape of treatment is undergoing a major shift. Research is moving toward therapies that aim to fix the underlying genetic cause rather than just managing the symptoms.
Gene Therapy: Replacing the Missing “Key”
The most advanced area of research involves adeno-associated virus (AAV) gene therapy.
- How it works: Scientists use a harmless virus (AAV) as a delivery truck to carry a healthy, functional copy of the G6PC1 gene directly into the liver cells [1][2].
- Current Status: A leading gene therapy candidate (DTX401) has reached Phase 3 clinical trials, the final stage before potential approval. Early results in adults showed that many patients were able to increase their fasting time and significantly reduce their reliance on cornstarch [3][2]. Long-term monitoring programs are now tracking these patients to see if the effects last for a decade or more [NCT06636383].
The Next Frontier: Gene and Base Editing
Beyond replacing the gene, researchers are looking at ways to “edit” the DNA itself.
- CRISPR-Cas9: This technology acts like molecular scissors to cut and repair the mutated gene [4][5].
- Base Editing: This is an even more precise tool that can change a single “letter” of DNA without cutting the strand [6]. A Phase 1/2 trial (BEAM-301) is currently recruiting adults with the specific R83C mutation to test if this can permanently correct the disease [NCT06735755].
New Pharmacological Targets
While gene therapy works on the “root” cause, other medications are being tested to help the liver and kidneys:
- Liver Health: Researchers are investigating “liver-specific thyromimetics” and medications like bezafibrate to help the liver process fat better and reduce the risk of tumors [2][7].
- Kidney Health: To protect the kidneys, scientists are exploring Wnt/beta-catenin inhibitors and SGLT2 inhibitors, which may help prevent the scarring and protein leakage associated with GSD Ia nephropathy [8].
A Note on Liver Transplantation
For some children, a liver transplant remains the only definitive way to “reset” the body’s metabolism [9].
- The Benefit: A successful transplant provides a new liver with working enzymes, which typically resolves the risk of hypoglycemia and other metabolic issues [9].
- The Risk: Transplantation is a major surgery that requires lifelong immunosuppressant drugs (to prevent the body from rejecting the new organ) and does not fix the enzyme deficiency in the kidneys [10]. It is usually reserved for children who cannot achieve metabolic stability through diet or those who develop suspicious liver tumors [9].
The progress in GSD Ia research is moving faster than ever before. While dietary therapy is your primary tool today, these emerging treatments offer a future where management might be significantly simpler and more effective [11][1].
Return to the Understanding Your Child’s GSD Ia Diagnosis.
Common questions in this guide
What is gene therapy for GSD Ia and how does it work?
Can CRISPR or base editing cure GSD Ia?
When is a liver transplant recommended for GSD Ia?
Are there new medications to protect the liver and kidneys in GSD Ia?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
Emerging treatments
Would gene therapy be an option for me, or is it still in clinical trials?
Transplant options
What would make a liver transplant an option for me?
Medications in research
Could medicines like bezafibrate or SGLT2 inhibitors be part of my care in the future?
Get notified when new evidence is published on Glycogen storage disease due to glucose-6-phosphatase deficiency type Ia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (11)
- 1
Liver-Directed Gene Therapy Mitigates Early Nephropathy in Murine Glycogen Storage Disease Type Ia.
Lee C, Pratap K, Zhang L, et al.
Journal of inherited metabolic disease 2025; (48(4)):e70048 doi:10.1002/jimd.70048.
PMID: 40443300 - 2
Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia.
Waskowicz LR, Zhou J, Landau DJ, et al.
Human molecular genetics 2019; (28(1)):143-154 doi:10.1093/hmg/ddy343.
PMID: 30256948 - 3
Bezafibrate Enhances AAV Vector-Mediated Genome Editing in Glycogen Storage Disease Type Ia.
Kang HR, Waskowicz L, Seifts AM, et al.
Molecular therapy. Methods & clinical development 2019; (13()):265-273 doi:10.1016/j.omtm.2019.02.002.
PMID: 30859111 - 4
CRISPR/Cas9-based double-strand oligonucleotide insertion strategy corrects metabolic abnormalities in murine glycogen storage disease type-Ia.
Samanta A, George N, Arnaoutova I, et al.
Journal of inherited metabolic disease 2023; (46(6)):1147-1158 doi:10.1002/jimd.12660.
PMID: 37467014 - 5
Correction of metabolic abnormalities in a mouse model of glycogen storage disease type Ia by CRISPR/Cas9-based gene editing.
Arnaoutova I, Zhang L, Chen HD, et al.
Molecular therapy : the journal of the American Society of Gene Therapy 2021; (29(4)):1602-1610 doi:10.1016/j.ymthe.2020.12.027.
PMID: 33359667 - 6
Base-editing corrects metabolic abnormalities in a humanized mouse model for glycogen storage disease type-Ia.
Arnaoutova I, Aratyn-Schaus Y, Zhang L, et al.
Nature communications 2024; (15(1)):9729 doi:10.1038/s41467-024-54108-1.
PMID: 39523369 - 7
A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia.
Zhou J, Waskowicz LR, Lim A, et al.
Thyroid : official journal of the American Thyroid Association 2019; (29(8)):1158-1167 doi:10.1089/thy.2019.0007.
PMID: 31337282 - 8
Inhibition of Wnt/β-catenin signaling reduces renal fibrosis in murine glycogen storage disease type Ia.
Lee C, Pratap K, Zhang L, et al.
Biochimica et biophysica acta. Molecular basis of disease 2024; (1870(1)):166874 doi:10.1016/j.bbadis.2023.166874.
PMID: 37666439 - 9
Liver Transplantation as a Metabolic Treatment in Glycogen Storage Disease Type Ia.
Atikcan Simsek DT, Avcı Dursun EM, Senay Ozcalik M, et al.
JCEM case reports 2025; (3(10)):luaf182 doi:10.1210/jcemcr/luaf182.
PMID: 40837847 - 10
Letter to the Editors: Concerning "Long-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia" by Lee et al.
Brooks ED, Kishnani PS, Koeberl DD
Journal of inherited metabolic disease 2018; (41(6)):913-914 doi:10.1007/s10545-018-0248-2.
PMID: 30255460 - 11
Impact of glycogen storage disease type I on adult daily life: a survey.
Garbade SF, Ederer V, Burgard P, et al.
Orphanet journal of rare diseases 2021; (16(1)):371 doi:10.1186/s13023-021-02006-w.
PMID: 34479584
This page provides information on experimental and emerging treatments for GSD Ia for educational purposes only. Always consult your child's metabolic specialist or geneticist before considering clinical trials or altering your current treatment plan.